BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32352887)

  • 1. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
    Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
    Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
    van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
    Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
    Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
    Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis.
    Rossi RE; Ciafardini C; Sciola V; Conte D; Massironi S
    Pancreas; 2018; 47(10):1249-1255. PubMed ID: 30325865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas.
    Børglum T; Rehfeld JF; Drivsholm LB; Hilsted L
    Clin Chem; 2007 Mar; 53(3):438-46. PubMed ID: 17259235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.
    Rogowski W; Wachuła E; Lewczuk A; Kolasińska-Ćwikła A; Iżycka-Świeszewska E; Sulżyc-Bielicka V; Ćwikła JB
    Future Oncol; 2017 May; 13(12):1069-1079. PubMed ID: 28095720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.
    Hong L; Wang Y; Zhang T; Zhang C; Wang L; Wang L; Wang Z; Zhong J
    Med Sci Monit; 2020 Nov; 26():e926635. PubMed ID: 33141811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
    Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
    Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
    Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.
    Molina R; Alvarez E; Aniel-Quiroga A; Borque M; Candás B; Leon A; Poyatos RM; Gelabert M
    Tumour Biol; 2011 Feb; 32(1):13-22. PubMed ID: 20730520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
    Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
    Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regular chromogranin A monitoring facilitated the early detection of a gastrointestinal neuroendocrine tumour in a patient with type 1 diabetes.
    Herold Z; Uhlyarik A; Herold M; Nagy P; Huszty GD; Rosta K; Doleschall M; Somogyi A
    Endokrynol Pol; 2020; 71(5):483-484. PubMed ID: 32856287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
    Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
    PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
    Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
    Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
    Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
    Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
    Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
    J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of the Acute Octreotide Suppression Test in Detecting Patients with Neuroendocrine Neoplasms.
    Kruljac I; Vičić I; Blaslov K; Kolak Z; Benković M; Kust D; Ladika Davidović B; Tometić G; Penavić I; Dabelić N; Vazdar L; Pavić T; Vrkljan M
    Neuroendocrinology; 2018; 107(3):284-291. PubMed ID: 30114698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours.
    Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E
    Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.